ISSUE: Healthcare systems across APAC are rapidly evolving due to economic pressures and demographic shifts. While the booming APAC MedTech market is expected to account for a third of global sales by 2025, there are significant discrepancies and variability across the region on how to assess the value of MedTech. Conversations about current and future trends in MedTech Health Technology Assessments (HTA) are important if we aim to improve patient outcomes and maintain healthcare sustainability by achieving value for money in healthcare spending. Joe Caputo will moderate and guide the discussion based on audience-selected topics of interest; while Jenifer Levinson, Chris Foteff and Dr Tamura Makoto will speak to global, Australian, and Japanese experiences of innovative MedTech HTA.

OVERVIEW: MedTech accounts for a significant proportion of healthcare spending, yet its assessment approaches and access policies are often out of the spotlight and at times lagging pharmaceuticals. In this panel, the current and future trends in MedTech HTA in APAC will be explored: How are MedTech assessment approaches evolving? What are the methodological differences in assessment approaches between MedTech and pharmaceuticals? How is value demonstrated in current assessment frameworks, and is there room for broader criteria to fully capture benefits conferred by innovative MedTech? How can industry engage with stakeholders to generate and present alternative evidence approaches that support value? This session hopes to advance the dialogue on MedTech assessment approaches and support the development of evidence generation for MedTech as part of the shift towards value-based healthcare. The panel will begin with an overview (15 minutes) of the above topics, followed by an interactive discussion (30 minutes) with the use of audience polling and Q&A to identify discussion points for input from the panellists and audiences alike.